抗动脉粥样硬化药物的研究进展  

Advances in Anti-atherosclerosis Medicines

作　　者：吴晓娟 林小娟 佟晓永 Xiaojuan;WU Xiaojuan;LIN Xiaoyong TONG(School of Pharmaceutical Sciences,Chongqing University,Chongqing 401331,China)

机构地区：[1]重庆大学药学院,重庆401331

出　　处：《生命科学仪器》2018年第6期16-24,15,共10页Life Science Instruments

基　　金：国家自然基金面上项目(81870343);中央高校基本科研业务费前沿交叉学科培育专项(2018CDQYYX0042)

摘　　要：动脉粥样硬化是一种严重危及人类健康的心血管疾病,引起广泛重视。常用的治疗药物以降低血脂、抗氧化以及抗血小板聚集为主。随着对动脉粥样硬化发病机制的深入研究,一些新型药物已陆续上市,如枯草溶菌素转换酶9抑制剂、微粒体转运蛋白抑制剂以及基因治疗药物等。此外,一系列具有血脂调节功能的新型药物目前已处于临床二期或三期的研究当中。本文对目前抗动脉粥样硬化药物的研究进展做简要综述。As a life-threatening cardiovascular disease, atherosclerosis attracts more and more attention. Medicines to lower lipid level, to lessen oxidants and to inhibit platelet aggregation are commonly used to treat atherosclerosis. With better understanding of the pathogenesis of atherosclerosis, new types of medicines come to market, including inhibitors to target proprotein convertase subtilisin/kexin type 9 or microsomal transfer protein, and gene therapy. In addition, there are a series of new medicines with lipid regulation are currently on clinical trial Phase II or Phase III. This review summarizes current progress of anti-atherosclerotic medicines.

关 键 词：动脉粥样硬化 抗动脉粥样硬化药物 调血脂类药物 

分 类 号：R966[医药卫生—药理学]